Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more - 2Peloton recalls more than 800,000 bikes after broken seat posts injure users
- 3Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- 4Inn The executives: A Remunerating Profession Decision for Energetic People
- 55 Instructive Toy Brands for Youngsters
- Picking Childcare Administrations for Your Loved ones
- Scaling New Levels: Rock Climbing Spots On the planet
- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- 5 Movies That Leaving an Imprint with Inventive Innovation
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- The Best 20 Photography Instagram Records to Follow
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
